N/A N=57 Randomized Double-blind Other

Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic Fatty Liver Disease

Bottom Line

View on ClinicalTrials.gov: NCT02875392 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: Change in ALT Index — 42.238; 33.524; 36.667; 36.238 U/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin (Other); placebo pills (Other)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Taipei Medical University WanFang Hospital
Primary completion: Oct 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in ALT Index	42.238; 33.524; 36.667; 36.238	—
PRIMARY Change in AST Index	28.095; 27.905; 25.286; 28.048	—
PRIMARY Change in HbA1c	5.871; 6.057; 5.79; 6.152	—

Summary

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Eligibility Criteria

Inclusion Criteria

Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD).

Exclusion Criteria

Patients were allergic to seafood.
Patients who take Vitamin E or Pioglitazone.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02875392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.